Get the Stockscreener App
8.47
0.12%
0.010
After Hours:
8.47
Chimerix Inc stock is traded at $8.47, with a volume of 1.77M.
It is up +0.12% in the last 24 hours and up +85.75% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$8.46
Open:
$8.45
24h Volume:
1.77M
Relative Volume:
0.26
Market Cap:
$788.11M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-9.1075
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+0.47%
1M Performance:
+85.75%
6M Performance:
+890.64%
1Y Performance:
+623.93%
1-Day Range:
$8.45
$8.48
1-Week Range:
$8.415
$8.48
52-Week Range:
$0.75
$8.48
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.47 | 788.11M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com South Africa
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Victoria Advocate
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - EIN News
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - EIN News
HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Top Medical Stocks To Add to Your Watchlist – March 5th - Defense World
Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX) - Defense World
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Best Pharmaceutical Stocks To Watch Today – March 5th - Defense World
Wedbush Reaffirms “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Chimerix downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Jazz Pharmaceuticals to acquire Chimerix for $935m - World Pharmaceutical Frontiers
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc.CMRX - The Malaysian Reserve
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Pharmaceuticals bids for Chimerix in $935m deal - MSN
CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz - MSN
Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio - Genetic Engineering & Biotechnology News
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online
Chimerix Stock Hold Rating: Limited Upside Due to Acquisition Offer Price Alignment - TipRanks
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz - BioCentury
Biotech Stock Chimerix (Nasdaq: CMRX) Soars on Acquisition News - Investorideas.com newswire
Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval - TipRanks
Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential - TipRanks
Demystifying Chimerix: Insights From 4 Analyst Reviews - Benzinga
Jazz Buys ChimerixA Good Deal To Make With Major Approval Catalyst In Play - Seeking Alpha
Jazz Pharmaceuticals to Acquire Chimerix for $935M - USA Herald
3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy - Law360
Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel - TipRanks
Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50 -March 05, 2025 at 12:31 pm EST - Marketscreener.com
Jazz expands in oncology with $935M deal for Chimerix - BioPharma Dive
North Carolina drugmaker sold in $935M deal - The Business Journals
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - Finansavisen
Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says - Marketscreener.com
Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. - Marketscreener.com
Jazz Pharma aims to boost cancer drug pipeline with $935 million buyoutSan Francisco Business Times - The Business Journals
Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals - TipRanks
Jazz Pharma to expand oncology portfolio with buy of Chimerix - The Pharma Letter
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):